WXIBF (WuXi Biologics (Cayman)) Days Payable: 30.70 (As of Dec. 2025) — 17% Below Median


WXIBF WuXi Biologics (Cayman) Inc WXIBF
97 GF Score
Price $4.00
GF Value $4.62
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is WuXi Biologics (Cayman) Days Payable?

WuXi Biologics (Cayman) WXIBF -9.09% 97 Days Payable is 30.70 as of Dec. 2025, which is 17% below its 10-year median of 36.92. GuruFocus rates WXIBF with a GF Score™ of 97/100 and a GF Value™ of $4.62 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 705 Biotechnology companies, WuXi Biologics (Cayman) ranks worse than 81.7% on this metric.

WuXi Biologics (Cayman)'s average Accounts Payable for the six months ended in Dec. 2025 was $145 Mil. WuXi Biologics (Cayman)'s Cost of Goods Sold for the six months ended in Dec. 2025 was $862 Mil. Hence, WuXi Biologics (Cayman)'s Days Payable for the six months ended in Dec. 2025 was 30.70.

The historical rank and industry rank for WuXi Biologics (Cayman)'s Days Payable or its related term are showing as below:

WXIBF' s Days Payable Range Over the Past 10 Years
Min: 26.5   Med: 36.92   Max: 120.2
Current: 28.81

During the past 12 years, WuXi Biologics (Cayman)'s highest Days Payable was 120.20. The lowest was 26.50. And the median was 36.92.

WXIBF's Days Payable is ranked worse than
81.7% of 705 companies
in the Biotechnology industry
Industry Median: 113.36 vs WXIBF: 28.81

WuXi Biologics (Cayman)'s Days Payable increased from Dec. 2024 (25.56) to Dec. 2025 (30.70). It may suggest that WuXi Biologics (Cayman) delayed paying its suppliers.


WuXi Biologics (Cayman) Days Payable Historical Data

* Premium members only.

The historical data trend for WuXi Biologics (Cayman)'s Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

WuXi Biologics (Cayman) Days Payable Chart

WuXi Biologics (Cayman) Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Days Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 41.67 31.41 29.45 26.43 28.13

WuXi Biologics (Cayman) Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.30 30.06 25.56 27.31 30.70

WXIBF vs VRTX, REGN, ALNY: Days Payable Comparison

For the Biotechnology subindustry, WuXi Biologics (Cayman)'s Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


WuXi Biologics (Cayman) Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s Days Payable distribution charts can be found below:

* The bar in red indicates where WuXi Biologics (Cayman)'s Days Payable falls into.


WXIBF
97GF Score
WuXi Biologics (Cayman) Inc WXIBF
Days Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

WuXi Biologics (Cayman) Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

WuXi Biologics (Cayman)'s Days Payable for the fiscal year that ended in Dec. 2025 is calculated as

Days Payable (A: Dec. 2025 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Dec. 2024 ) + Accounts Payable (A: Dec. 2025 )) / count ) / Cost of Goods Sold (A: Dec. 2025 )*Days in Period
=( (102.62 + 154.978) / 2 ) / 1671.329*365
=128.799 / 1671.329*365
=28.13

WuXi Biologics (Cayman)'s Days Payable for the quarter that ended in Dec. 2025 is calculated as:

Days Payable (Q: Dec. 2025 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Jun. 2025 ) + Accounts Payable (Q: Dec. 2025 )) / count ) / Cost of Goods Sold (Q: Dec. 2025 )*Days in Period
=( (135.011 + 154.978) / 2 ) / 861.986*365 / 2
=144.9945 / 861.986*365 / 2
=30.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Days Payable →
What does a Days Payable of 30.70 mean?
WuXi Biologics (Cayman) (WXIBF) has a Days Payable of 30.70 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on WuXi Biologics (Cayman) and its competitors. This is 17% below median its historical median of 36.92. Over the past decade, WuXi Biologics (Cayman)'s Days Payable has ranged from 26.50 to 120.20. According to the industry distribution chart, WuXi Biologics (Cayman) ranks #576 out of 705 companies in the Biotechnology industry, placing it in the top 81.7%.
Is WuXi Biologics (Cayman)'s Days Payable too high?
WuXi Biologics (Cayman)'s current Days Payable of 30.70 is 17% below median its 10-year median of 36.92. Over the past 10 years, this metric has ranged from a low of 26.50 to a high of 120.20. The Biotechnology industry median Days Payable is 113.36. WuXi Biologics (Cayman)'s value of 30.70 is 72.9% below this industry median. Based on the distribution chart, WuXi Biologics (Cayman) ranks #576 out of 705 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, WuXi Biologics (Cayman) has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does WuXi Biologics (Cayman)'s Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, WuXi Biologics (Cayman) ranks #576 out of 705 companies for Days Payable. This places WuXi Biologics (Cayman) in the lower half of its industry. The industry median Days Payable is 113.36. WuXi Biologics (Cayman)'s value of 30.70 is 72.9% below this benchmark. Historically, WuXi Biologics (Cayman)'s own Days Payable has ranged from 26.50 to 120.20 over the past decade. While the company's 10-year median is 36.92 vs. the industry median of 113.36, WuXi Biologics (Cayman) has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.36, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. WuXi Biologics (Cayman)'s current Days Payable of 30.70 is 72.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on WuXi Biologics (Cayman) and its competitors. For the Biotechnology industry, the median Days Payable is 113.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WuXi Biologics (Cayman)'s current Days Payable is 30.70, which is 17% below median its own 10-year median of 36.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi Biologics (Cayman) stock overvalued right now?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) (WXIBF) is currently considered Modestly Undervalued. The stock's GF Value™ is $4.62, compared to a current price of $4.00 — trading 13.4% below its estimated fair value. The current Days Payable is 30.70, which is 17% below median its 10-year median of 36.92 and 72.9% below the Biotechnology industry median of 113.36. WuXi Biologics (Cayman)'s overall GF Score™ is 97/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For WuXi Biologics (Cayman) (WXIBF), the current Days Payable is 30.70 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is WuXi Biologics (Cayman) (WXIBF) Overvalued in 2026?

Based on GuruFocus' analysis, WuXi Biologics (Cayman) stock appears to be undervalued. The current stock price of $4.00 is trading 13.4% below its estimated GF Value™ of $4.62. GuruFocus considers WuXi Biologics (Cayman) to be Modestly Undervalued.

Key valuation signals for WXIBF:

  • Days Payable: 30.70 (17% below median its 10-year median of 36.92)
  • GF Value™: $4.62 vs. price of $4.00 (13.4% below fair value)
  • GF Score™: 97/100 with 3 warning signs
  • Industry Position: 72.9% below the Biotechnology median (#576 of 705)

No single metric tells the full story. See the WXIBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


WuXi Biologics (Cayman) Business Description

Address No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing refining and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
97GF Score

Get the complete analysis for WXIBF

Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.00
Price
$4.62
GF Value